U.S. Stock Night Market Movements
BGM fell 18.26% in the night market. Based on recent key news:
<ol>
<li>
On May 14, BGM Group submitted multiple Form 3 documents in the EDGAR system, involving the appointment of several directors and executives. The release of these documents may raise market concerns about changes in the company's governance structure, leading to a significant drop in stock prices.
</li>
<li>
On May 14, the appointment document of BGM Group's Chief Financial Officer Zhai Yaxuan was also published in the EDGAR system, further intensifying market concerns about internal management changes, affecting investor confidence.
</li>
<li>
On May 14, the appointment document of BGM Group's director Lou Zefei was released, causing market unease over the frequent changes in the company's leadership, putting pressure on stock prices. The market remains vigilant about changes in the company's governance structure.
</li>
</ol>
Stocks with High Trading Volume in the Industry
Eli Lilly fell 0.40% in the night market. Based on recent key news:
<ol>
<li>
On May 15, Eli Lilly engaged in political lobbying in Washington, investing over $10 million to influence drug pricing policies. This move aims to protect the market position of its GLP-1 drugs, leading to stock price fluctuations.
</li>
<li>
On May 17, Eli Lilly announced that its new drug Orforglipron performed excellently in clinical trials, with a weight maintenance rate significantly higher than the placebo group, boosting market confidence in its weight loss drugs.
</li>
<li>
On May 16, Eli Lilly partnered with the Caitlin Clark Foundation to open a community sports field in Indianapolis, reflecting its active investment in community engagement and brand image. The competition in the GLP-1 drug market is intensifying, with increased policy risks.
</li>
</ol>
Novo Nordisk fell 1.05% in the night market. Based on recent news:
<ol>
<li>
On May 16, following the implementation of new regulations in China, Novo Nordisk may need to supplement data protection applications to further confirm and extend its protection period under the Swiss Free Trade Agreement. This increases the company's compliance costs in the Chinese market, affecting investor confidence.
</li>
<li>
On May 15, the abuse of semaglutide in the Chinese market is severe, disrupting the pharmaceutical market order and posing significant health risks to abusers. This has raised market concerns about regulatory risks for Novo Nordisk products, leading to a drop in stock prices.
</li>
<li>
On May 15, competition in the GLP-1 drug market intensified, with significant price adjustments for semaglutide and tirzepatide. Novo Nordisk's market share in the weight loss drug sector is under pressure, affecting stock performance. The competition in the GLP-1 drug market is intensifying, with significant price adjustments.
</li>
</ol>
Johnson &amp; Johnson fell 0.30% in the night market. Based on recent key news:
<ol>
<li>
On May 16, major market averages on Wall Street declined, tech stocks fell, and U.S. Treasury yields rose. This macroeconomic change put pressure on large stocks like Johnson &amp; Johnson, leading to a drop in stock prices. Source: Wall Street
</li>
<li>
On May 16, analysts pointed out that Johnson &amp; Johnson's strong position in the MedTech market and diversified product portfolio may face financial performance pressure, but its scale and blue-chip dividend record are still viewed positively. This analyst's opinion has impacted the stock price. Source: Analyst report
</li>
<li>
On May 16, Soros Fund Management disclosed a new equity holding in Johnson &amp; Johnson in SEC filings, which may affect market sentiment. Source: SEC filings. Technology stocks declined, and Treasury yields rose
</li>
</ol>

BGM fell 18.26% in the night session; Eli Lilly fell 0.40% in the night session, with a transaction volume of USD 2.09 million; Novo Nordisk fell 1.05% in the night session, with a transaction volume of USD 1.63 million; Johnson & Johnson fell 0.30% in the night session, with a transaction volume of USD 731,800

Price Alert

Eli Lilly

Novo Nordisk AS

Johnson & Johnson

U.S. stock night trading volatility: BGM fell 18.26% in after-hours trading, frequent executive changes raise market concerns about corporate governance